Large Volume Wearable Injectors Market (4th Edition), 2018-2030

Driven by a growing pipeline of drugs for the treatment of chronic disorders, the large volume wearable injectors market is anticipated to grow at an annualized rate of over 40%, predicts Roots Analysis
By: Roots Anlaysis
Spread the Word
Listed Under



London City - London, Greater - England


LONDON - Jan. 28, 2019 - PRLog -- London

Roots Analysis ( has announced the addition of "Large Volume Wearable Injectors Market (4th Edition), 2018-2030 (" report to its list of offerings.

Harsimran Kaur, the principal analyst, stated, "The large volume wearable injectors have captured the interest of both drug developers and medical device manufacturers. This can be attributed to the benefits offered by these devices, including user-friendly features, convenient mode of administration and reduced healthcare cost. In fact, over 50 devices are currently under development or are approved for the delivery of both insulin and non-insulin drugs."

The report presents opinions on several key aspects of the market. Among other elements, it includes:
1.  A detailed review of the overall landscape of the large volume wearable injectors market, highlighting the contributions of industry players related to the delivery of both insulin and non-insulin drugs, along with key device specifications. Around 17% of such devices have the capability to hold 10-15 ml of drug, while 23% of the devices have a maximum storage capacity of more than 15 ml.

2.  A comprehensive product competitiveness analysis of all large volume wearable injectors that we came across, taking into consideration the supplier power (based on the year of establishment) and product specifications, such as type of device, type of dose, maximum volume of the device, usability, allowed route of administration, connectivity with the mobile application, and availability of an integrated continuous glucose monitoring / blood glucose monitoring (CGM / BGM) system in case of insulin devices.

3.  Elaborate profiles of prominent product developers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products. More than 10 drug device combinations are currently being evaluated for delivery of non-insulin drugs; of these, two are already approved by the USFDA; these are Neulasta® (pegfilgrastim) OnPro™ Kit (Amgen / Insulet) and Pushtronex™ System (Amgen / West Pharmaceuticals).

4. An in-depth analysis of the various patents that have been submitted / filed related to large volume wearable injectors, since 1984. It also highlights the key parameters associated with the patents, including information on patent type, patent offices, Cooperative Patent Classification (CPC) classification, emerging areas (in terms of number of patents filed / granted) and leading industry players (in terms of size of intellectual property portfolio). Close to 2,000 patents pertaining to these devices have been filed till September 2018. An analysis of these patents revealed that automated self-injection devices, with advanced features, are gradually gaining traction amongst patients with chronic disorders.

5. A social media analysis depicting prevalent and emerging trends, and the popularity of large volume wearable injectors, as observed on the social media platform, Twitter.

6.  A comprehensive clinical trial analysis of completed, ongoing and planned studies of various large volume wearable injector products. For the purpose of this analysis, we considered the clinical studies that started in 2010, and analyzed them on the basis of various parameters. It is worth noting that close to 50% trials assessed the potential of using large volume wearable injectors for delivery of drugs intended for the treatment of neurological disorders. This is followed by the trials conducted to evaluate the effect of large volume wearable injectors in patients suffering from cardiovascular disorders (23%) and cancer (13%).

7. A case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of wearable injectors. It includes short descriptions of the manufacturing services provided by contract service providers in the making of various device components (primary containers), infusion sets, adhesives, closures and injection moldings.

8. A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with large volume wearable injectors in the near future, based on an in-depth analysis of potential candidates, taking into consideration multiple parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). Of the various marketed / under development drug molecules, close to 80 drugs demonstrated a relatively higher potential to be delivered via large volume wearable injectors and are most likely to be evaluated in different drug-device combinations in the near future.

Kaur further remarked, "The historical and current uptake trends of large volume wearable injectors for insulin delivery clearly demonstrate the growing popularity of these devices among patients suffering from diabetes. As the developers strive to provide more user-friendly and advanced wearable devices, we anticipate that the adoption of large volume wearable injectors would increase in the coming years for delivery of non-insulin drugs as well." The report features inputs from a number of eminent industry stakeholders, with detailed transcripts of discussions held with the following experts:

1.     Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
2.     Mike Hooven (President and Chief Executive Officer, Enable Injections)
3.     Mark Banister (Chief Executive Officer, Medipacs)
4.     Pieter Muntendam (President and Chief Executive Officer, scPharmaceuticals)
5.     Mindy Katz (Director of Product, Sorrel Medical)
6.     Jesper Roested (Chief Executive Officer, Subcuject)
7.     Graham Reynolds (Vice President & General Manager, Global Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services)

The research covers detailed profiles and assesses product portfolios of several companies, including (illustrative list, no selection criteria):

1.     Becton Dickinson
2.     Bespak
3.     Insulet
4.     Medtronic
5.     Roche
6.     Sonceboz
7.     Enable Injections
8.     Sensile Medical
9.     SteadyMed Therapeutics
10.   West Pharmaceutical Services
11.   Weibel CDS
12.   Cellnovo
13.   CeQur
14.   Debiotech
15.   Eli Lilly
16.   PharmaSens
17.   SOOIL Development
18.   Tandem Diabetes Care

For additional details, please visit or email

Media Contact
Gaurav Chaudhary
Posted By:*** Email Verified
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Roots Analysis PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share